Full-Time
Product Engineer 1
Research and Development
Posted on 7/29/2026
Cooper Companies
201-500 employees
Global medical devices and vision care
Compensation Overview
$60k - $90k/yr
Bridgeport, CT, USA
In Person
 Software Engineering (1) |
|---|
Get referred to Cooper Companies
See people who can refer or advise you
- Strong knowledge of Mechanical Engineering principles, including mechanics and materials science.
- Proficiency in Solidworks, 3D modelling, assemblies and engineering drawings according to ASME Y14 series.
- Understanding of product development processes, including design controls, risk management, and design verification and validation.
- Excellent problem-solving and analytical skills.
- Strong English language communication skills (written and oral). Ability to author reports, protocols, procedures, presentations and other related documents. Ability to effectively communicate to peers as well as management.
- Ability to work in a fast-paced high pressure environment and meet project deadlines.
- Create testable design inputs from user needs, develop protocols and execute testing.
- Design and develop mechanical systems and components for medical devices.
- Conduct feasibility studies and provide technical support for new products and existing products.
- Create and maintain 3D models, assemblies, engineering drawings and specifications according to ASME Y14.5.
- Ensure product compliance with relevant regulatory and industry standards.
- Collaborate with cross-functional teams including operations, supply chain, regulatory and quality to ensure timely delivery of projects.
- Manage the entire change control process from initiation to production.
- Participate in design reviews and provide constructive feedback to improve designs.
- Cross-disciplinary education and/or experience such as mechatronic, electro-mechanical, mechanical-materials, electrical-biomedical, etc is highly desirable.
Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
1958
Get referred to Cooper Companies
See people who can refer or advise you
Simplify's Take
What believers are saying
- EMEA revenue grew 7.9% to $289.7 million in the April 2026 quarter.
- Adjusted EPS of $1.21 beat the $1.10 estimate, showing operating leverage.
- Full-year revenue guidance of $4.29 billion to $4.32 billion supports continued expansion.
What critics are saying
- Alcon and Johnson & Johnson pressure pricing and shelf space in contact lenses.
- Asia Pacific revenue missed expectations, exposing weaker execution in a key growth region.
- Fertility demand depends on clinic spending and IVF volumes, which swing with reimbursement.
What makes Cooper Companies unique
- CooperVision pairs soft contact lenses with strong toric, multifocal, and myopia-management niches.
- CooperSurgical spans fertility, genomics, cryostorage, contraception, and women’s surgical devices.
- The company runs two specialized businesses under one global medical-device platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
Company News
The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.
CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.
CooperCompanies reported Q4 revenues of $1.02 billion, up 6.2% year on year, meeting analysts' expectations. The medical devices manufacturer, which focuses on vision care and women's health products, delivered an impressive beat on full-year earnings per share guidance, though organic revenue was in line with estimates. The company raised both earnings and free cash flow guidance following strong profitability and cash generation. Operating margins exceeded expectations due to synergies from last year's reorganisation. President and CEO Al White highlighted momentum from product launches, including the premium MyDay portfolio and early traction from MyDay MiSight. Across the medical devices and supplies sector, six tracked companies reported mixed Q4 results, with revenues collectively beating consensus estimates by 1.9%. Share prices have declined 9.5% on average since earnings announcements.
Cooper Companies, a California-based medical devices manufacturer, has declined 12.5% over the past 52 weeks, underperforming the Dow Jones Industrial Average's 13.2% gain during the same period. The company, valued at $13.9 billion, has fallen 20.9% from its December 2025 peak of $89.83. Shares dropped 2.2% on 5 March following mixed Q1 2026 results. Whilst revenue rose 6% year-over-year to $1 billion and adjusted earnings per share increased 20% to $1.10, both beating estimates, investors focussed on weak organic revenue growth and challenges in the Asia Pacific region. The stock has traded below its 200-day and 50-day moving averages since early March. Despite the decline, analysts maintain a "Moderate Buy" rating with a mean price target of $90.81, suggesting 27.8% upside potential.